3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer

Sarah P. Blagden(Churchill Hospital), Hani Gabra(Royal Children's Hospital), D. Smith, Martin Buck(Imperial College London), Beth Ann Reedy, Damien McAleer, M. Hall, Linda Mileshkin(Peter MacCallum Cancer Centre), S. Anandra, Tarek Meniawy(St John of God Subiaco Hospital), Robert Noble, Shirley Wong(Western Hospital), S. Morris, Anne Hamilton(Royal Women's Hospital)

European Journal of Cancer

November 1, 2014

10.1016/s0959-8049(14)70129-7

Cited by 8

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes

|Nature reviews. Cancer|2011|1.5k

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

|Nature reviews. Cancer|2015|1.4k

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

|The Lancet|2024|729

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

|The Lancet|2019|223

Managing membrane stress: the phage shock protein (Psp) response, from molecular mechanisms to physiology

|FEMS Microbiology Reviews|2010|222